Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 14.72M shares outstanding
USInhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms.
Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function.
The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Douglas G. Forsyth
Director
Jon Faiz Kayyem, Ph.D.
Director
Kimberly Manhard
Director
Kristiina Vuori, M.D., Ph.D.
Director
Employees
108
Country
US
Sector
Healthcare
Website
inhibrx.com
Loading congressional disclosures…
based on 14.72M shares outstanding
US30d Avg
252.47K
60d Avg
312.60K
90d Avg
281.05K
